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Discussion {#onco12963-sec-0006}
==========

Nivolumab is a human monoclonal antibody that targets the programmed cell death‐1 receptor. Nivolumab has been approved for the treatment of various types of cancer in \>60 countries, and numerous clinical trials are ongoing. Although the overall efficacy, safety, and PK of nivolumab have been extensively studied, these data were established in predominantly Caucasian populations. The safety and intensive PK of nivolumab flat‐dose regimens (240 mg Q2W or 360 mg once every 3 weeks) have not been assessed in Chinese patients.

This single‐center, open‐label, phase I/II study assessed the safety and tolerability of nivolumab in Chinese adult patients with previously treated, advanced or recurrent NPC or other solid tumors. Secondary objectives were PK, immunogenicity, and preliminary antitumor activity.

There were no new safety signals for nivolumab in Chinese patients, and safety profiles were consistent with prior clinical studies (Table [1](#onco12963-tbl-0001){ref-type="table"}). Of 46 evaluable patients, 35 experienced TRAEs; there were no grade 4--5 TRAEs, and only two were grade 3 (asthenia, 3 mg/kg cohort; hypochloremia, 240 mg cohort). Two serious TRAEs occurred, a grade 4 hyponatremia (240 mg cohort) and an indeterminate grade pancreatitis and cerebellar hemorrhage (3 mg/kg cohort) that led to discontinuation.

###### Summary of treatment‐related adverse events and serious adverse events

![](onco12963-tbl-0001){#nlm-graphic-1}

Pancreatitis and cerebellar hemorrhage of indeterminate grade that occurred in one patient in the 3 mg/kg cohort.

Data for TRAEs (any grade) occurring in ≥10% of patients per treatment cohort or patient group.

Abbreviations: NPC, nasopharyngeal carcinoma; SAE, serious adverse event; TRAE, treatment‐related adverse event.

Intensive PK profiles were characterized after first nivolumab dose and at steady state in all cohorts; PK data were compared with results from global patients and revealed no ethnic sensitivity at 3 mg/kg Q2W (Table [2](#onco12963-tbl-0002){ref-type="table"}). At data cutoff, antidrug antibodies were detected in 1 of 41 patients tested (3 mg/kg cohort).

###### Summary of pharmacokinetic parameters of nivolumab treatment (3 mg/kg, once every 2 weeks) in Chinese and global patient populations

![](onco12963-tbl-0002){#nlm-graphic-3}

Data for the global patient population are from the phase I CA209003 study \[[1](#onco12963-bib-0001){ref-type="ref"}\].

Geometric mean (% coefficient of variation \[CV\]) for all parameters except for T~max~ (median \[range\]) and t~1/2‐effective~ (mean \[% CV\] for the CheckMate 077 study and mean \[SD\] for the global patient data.

*n* = 5 for AUC~tau~ and t~1/2‐effective~.

Abbreviations: ---, data not available; AUC~tau~, area under the serum concentration‐time curve for a dosing interval; C~max~, maximum serum concentration; PK, pharmacokinetic; t~1/2‐effective~, effective half‐life calculated using the formula $\frac{\tau \bullet \mathit{\ln}\left( 2 \right)}{\mathit{\ln}\left\lbrack \frac{\mathit{AI}}{\mathit{AI} - 1} \right\rbrack}$, where t is the dosing interval and AI is the ratio of AUC~tau~ at steady state to that at single dose; T~max~, time taken to reach maximum concentration.

Among the 32 patients (70%) with NPC, the objective response rate was 13% (95% confidence interval \[CI\]: 4--29) and the disease control rate was 66% (95% CI: 47--81). The median follow‐up duration was 7.5 months (range: 0.8--24.7 months), and median progression‐free survival was 3.5 months (95% CI: 1.8--5.5).

In this pretreated group of patients with predominantly NPC, our study showed that the safety, tolerability, and PK (3 mg/kg) of nivolumab are similar in Chinese and global populations. Furthermore, promising antitumor activity of nivolumab in NPC suggests that further studies are warranted.

Trial Information {#onco12963-sec-0007}
=================

**Disease**Advanced cancer/solid tumor only**Stage of Disease/Treatment**Metastatic/advanced**Prior Therapy**≥1 prior regimen**Type of Study ‐ 1**Phase I/II**Type of Study ‐ 2**Dose evaluation and cohort expansion**Primary Endpoint**Safety and tolerability**Secondary Endpoint**Pharmacokinetics**Secondary Endpoint**Immunogenicity**Secondary Endpoint**Efficacy**Additional Details of Endpoints or Study Design** Dose evaluation and cohort expansion phases: Based on global clinical experience, a nivolumab dose of 3 mg/kg was selected for the initial 8‐week dose evaluation phase. The study proceeded to the cohort expansion phase following the absence of dose‐limiting toxicities in any of the treated patients. In the cohort expansion phase, three patient cohorts received differing nivolumab regimens (3 mg/kg, 240 mg, and 360 mg) until disease progression or unacceptable toxicity, for a maximum of 2 years. At the time of data analysis, a fourth expansion cohort (480 mg flat dose, once every 4 weeks \[Q4W\]) was active and not yet recruiting. **Investigator\'s Analysis**Drug tolerable, efficacy undetermined

Drug Information {#onco12963-sec-0008}
================

**Drug 1** **Generic/Working Name**Nivolumab**Trade Name**Opdivo**Company Name**Bristol‐Myers Squibb Pharmaceuticals Ltd.**Drug Type**Antibody**Drug Class**Immune therapy**Dose**3 mg/kg, 240 mg, 360 mg**Route**IV**Schedule of Administration** Dose evaluation phase: 3 mg/kg Q2W for 8 weeks. Cohort expansion phase: 3 mg/kg Q2W; or 240 mg flat dosing Q2W; 360 mg flat dosing once every 3 weeks (Q3W); 480 mg flat dosing Q4W. Note: At the time of data analysis, a fourth expansion cohort (480 mg flat dose Q4W) was active and not yet recruiting. The treatment cycles for the dose evaluation phase and 3 mg/kg Q2W and 240 mg Q2W dose expansion cohorts were 8 weeks\' duration (four doses per cycle), whereas the treatment cycles for the 360 mg Q3W cohort were 3 weeks\' duration (one dose per cycle). 

Dose Escalation Table {#onco12963-sec-1008}
=====================

imageJohn Wiley & Sons, Ltd.[^1]

Dose Information: Evaluable Safety and PK Population {#onco12963-sec-1018}
====================================================

imageJohn Wiley & Sons, Ltd.[^2]

Patient Characteristics {#onco12963-sec-0009}
=======================

Number of Patients, Male31Number of Patients, Female15StageAdvanced or recurrentAgeMedian (range): 48 (27--72)Number of Prior Systemic TherapiesMedian (range): 3 (1 to ≥4)Performance Status: ECOG0 --- 171 --- 29OtherRace: Asian 100%; Complete baseline demographic and disease characteristics are presented in Table [3](#onco12963-tbl-0003){ref-type="table"}.Cancer Types or Histologic SubtypesHepatocellular carcinoma, 2Lung, non‐small cell, 11Nasopharyngeal carcinoma, 32Not reported, 1

Primary Assessment Method {#onco12963-sec-0011}
=========================

TitleNew assessmentTitleTotal patient populationNumber of Patients Screened51Number of Patients Enrolled51Number of Patients Evaluable for Toxicity46Number of Patients Evaluated for Efficacy46Evaluation MethodRECIST 1.1Response Assessment CR*n* = 0 (0%)Response Assessment PR*n* = 6 (13%)Response Assessment SD*n* = 20 (43%)Response Assessment PD*n* = 18 (39%)Response Assessment OTHER*n* = 2 (4%)Outcome NotesRegarding "Response Assessment OTHER," responses could not be determined for these patients.

Adverse Events {#onco12963-sec-3012}
==============

imageJohn Wiley & Sons, Ltd.[^3]

Serious Adverse Events {#onco12963-sec-0041}
======================

imageJohn Wiley & Sons, Ltd.[^4]

Assessment, Analysis, and Discussion {#onco12963-sec-0012}
====================================

CompletionInterim analysis, study ongoing (480 mg cohort recruiting)Investigator\'s AssessmentDrug tolerable, efficacy undetermined

 {#onco12963-sec-2012}

Nivolumab is a human monoclonal antibody that targets the programmed death receptor‐1 (PD‐1) and has been approved for the treatment of various types of cancer in ≥60 countries \[[2](#onco12963-bib-0002){ref-type="ref"}\]. Early‐stage clinical trials of anti‐PD‐1 therapies have shown promising activity in recurrent or metastatic nasopharyngeal carcinoma (NPC), a common cancer in southeast Asia and North Africa \[[3](#onco12963-bib-0003){ref-type="ref"}\], \[[4](#onco12963-bib-0004){ref-type="ref"}\], with objective response rates (ORRs) of 21%--34% \[[5](#onco12963-bib-0005){ref-type="ref"}\], \[[6](#onco12963-bib-0006){ref-type="ref"}\], \[[7](#onco12963-bib-0007){ref-type="ref"}\].

The overall efficacy, safety, and pharmacokinetics (PK) of nivolumab are based on clinical data from approximately 17,600 global (predominantly Caucasian) patients \[[8](#onco12963-bib-0008){ref-type="ref"}\], \[[9](#onco12963-bib-0009){ref-type="ref"}\], \[[10](#onco12963-bib-0010){ref-type="ref"}\], \[[11](#onco12963-bib-0011){ref-type="ref"}\], \[[12](#onco12963-bib-0012){ref-type="ref"}\], \[[13](#onco12963-bib-0013){ref-type="ref"}\], \[[14](#onco12963-bib-0014){ref-type="ref"}\], \[[15](#onco12963-bib-0015){ref-type="ref"}\]. The safety of nivolumab 3 mg/kg administered once every 2 weeks (Q2W) has been assessed in Chinese patients in the CheckMate 078 study (NCT2613507), leading to its approval for the treatment of non‐small cell lung cancer in China \[[16](#onco12963-bib-0016){ref-type="ref"}\]; nivolumab 240 mg Q2W is approved in the U.S. \[[2](#onco12963-bib-0002){ref-type="ref"}\] and Japan \[[17](#onco12963-bib-0017){ref-type="ref"}\].

This study therefore aimed to assess the safety, tolerability, and PK of nivolumab in Chinese patients with previously treated, advanced or recurrent NPC or other solid tumors. Importantly, this is the first study to assess the safety and intensive PK of 240 mg and 360 mg flat‐dose regimens in Chinese patients.

This was an open‐label, single‐center, phase I/II study (CheckMate 077; NCT02593786) of nivolumab monotherapy. The study comprised a dose evaluation phase (3 mg/kg Q2W, 60‐minute intravenous \[IV\] infusion) and cohort expansion phase (3 mg/kg Q2W, flat dose 240 mg Q2W and 360 mg once every 3 weeks \[Q3W\]; 30‐minute IV infusion) and consisted of a screening period (≤28 days), a treatment period (until disease progression or intolerable toxicities), and a follow‐up period (≤100 days).

Included patients were Chinese adults (aged ≥18 years), Eastern Cooperative Oncology Group Performance Status 0 or 1, with histologically or cytologically confirmed solid tumors that were clinically advanced or recurrent, who had progressed after ≥1 prior line of systemic therapy. Exclusion criteria included central nervous system metastases, prior malignancy (except for nonmelanoma or certain in situ cancers, or complete remission ≥2 years), autoimmune disease, prior immunotherapy, active tuberculosis infection, pregnancy, or immunosuppressive agent treatment.

At data cutoff, 51 patients were enrolled, of whom 46 (90%) received ≥1 dose of study treatment and were evaluable for safety (Fig. [1](#onco12963-fig-0001){ref-type="fig"}). Baseline patient characteristics are presented in Table [3](#onco12963-tbl-0003){ref-type="table"}; the median patient age was 48 years (range: 27--72 years), 67% (31) were male, and 28 (61%) had received \>2 prior lines of systemic anticancer therapy. Forty‐three patients (93%) had discontinued during the treatment period, mostly because of disease progression (35 patients, 76%), and only 1 patient because of study drug toxicity. Three patients (7%) discontinued because of adverse events (AEs) unrelated to nivolumab.

At data cutoff, median (range) duration of treatment was 11.7 (2.0--105.1) weeks for the 3 mg/kg cohort, 16.6 (2.0--98.7) weeks for the 240 mg cohort, and 24.1 (3.0--48.9) weeks for the 360 mg cohort. The median (range) cumulative dose per subject were 1,920.0 (240.0--11,520.0) mg and 2,880.0 (360.0--5,076.0) mg for the 240 mg and 360 mg cohorts, respectively, and 18.2 (3.0--152.3) mg/kg in the 3 mg/kg cohort.

No dose‐limiting toxicities were observed during the dose evaluation phase (*n* = 8) or dose expansion phase. Incidence of treatment‐related adverse events (TRAEs) was similar across cohorts (Table [1](#onco12963-tbl-0001){ref-type="table"}). Overall, no new safety signals were identified, with safety profiles consistent with prior global studies and in line with a phase III study in Chinese patients (NCT02613507) \[[8](#onco12963-bib-0008){ref-type="ref"}\], \[[9](#onco12963-bib-0009){ref-type="ref"}\], \[[10](#onco12963-bib-0010){ref-type="ref"}\], \[[11](#onco12963-bib-0011){ref-type="ref"}\], \[[12](#onco12963-bib-0012){ref-type="ref"}\], \[[13](#onco12963-bib-0013){ref-type="ref"}\], \[[14](#onco12963-bib-0014){ref-type="ref"}\], \[[15](#onco12963-bib-0015){ref-type="ref"}\], \[[16](#onco12963-bib-0016){ref-type="ref"}\], \[[18](#onco12963-bib-0018){ref-type="ref"}\], \[[19](#onco12963-bib-0019){ref-type="ref"}\], \[[20](#onco12963-bib-0020){ref-type="ref"}\]. There were two grade ≥3 TRAEs: one grade 3 asthenia in the 3 mg/kg cohort and one grade 3 hypochloremia in the 240 mg cohort. Treatment‐related serious adverse events were a grade 4 hyponatremia (240 mg cohort) and pancreatitis and cerebellar hemorrhage of indeterminate grade (one patient, 3 mg/kg cohort) that led to discontinuation of treatment. There were no incidences of death associated with nivolumab.

In terms of all‐cause AEs, incidence of hypothyroidism was 30% in the 240 mg cohort (three patients each experienced a grade 1 or 2 event) and 55% in the 360 mg cohort (five patients with a grade 1 event and one patient with a grade 2 event) compared with no such reported events in the 3 mg/kg cohort. This most likely reflects the increased proportions of patients with NPC in the flat‐dosing cohorts who had received prior radiotherapy.

Intensive PK profiles of nivolumab were characterized following a single dose (Cycle 1, Day 1) and multiple doses (3 mg/kg and 240 mg: Cycle 3, Day 1; 360 mg: Cycle 6, Day 1). Single‐dose nivolumab resulted in rank‐order differences in the mean serum concentration versus time profiles, with the highest mean concentrations observed for the 360 mg Q3W flat dose, followed by the 240 mg Q2W flat dose and the 3 mg/kg Q2W dose (Fig. [2](#onco12963-fig-0002){ref-type="fig"}A). PK parameters were assessed via noncompartmental analysis and showed similar rank‐order relationships for the geometric mean area under the serum concentration‐time curve for a dosing interval (AUC~tau~), maximum serum concentration and concentration at the end of the dosing interval (Table [4](#onco12963-tbl-0004){ref-type="table"}).

Steady state was reached by approximately Cycle 3 (Week 17: 3 mg/kg and 240 mg flat dose) or Cycle 6 (Week 16: 360 mg flat dose; Fig. [2](#onco12963-fig-0002){ref-type="fig"}C). At steady state, the mean serum nivolumab concentration profiles over time were similar between the flat‐dose cohorts and appeared lower for the 3 mg/kg cohort (Fig. [2](#onco12963-fig-0002){ref-type="fig"}B). The geometric mean AUC~tau~ for the 360 mg flat‐dose cohort was approximately 41% and 72% higher than for the 240 mg flat‐dose and 3 mg/kg cohorts, respectively. However, when normalized by dosing interval, the AUC~tau~ values were comparable, indicating that the different dosing regimens yielded comparable average concentrations at steady state. The mean effective half‐life varied between cohorts (521--752 hours, or 21.7--31.3 days) but was within ±5 days of the mean elimination half‐life of 25 days reported previously \[[2](#onco12963-bib-0002){ref-type="ref"}\].

At 3 mg/kg, nivolumab exposure in Chinese patients was similar to that of patients in a global phase I study (NCT00730639), as demonstrated by a cross‐study comparison (Table [2](#onco12963-tbl-0002){ref-type="table"}) \[[1](#onco12963-bib-0001){ref-type="ref"}\]. These data are also in agreement with a recent phase I study of nivolumab in advanced solid tumors in Korean patients, in which PK data were shown to be comparable to U.S. and Japanese populations \[[21](#onco12963-bib-0021){ref-type="ref"}\].

Immunogenicity was assessed via antidrug antibody (ADA) status (Table [5](#onco12963-tbl-0005){ref-type="table"}). Of 41 evaluable patients, only 1 patient (3 mg/kg cohort) was ADA positive after treatment. None of the patients were persistently ADA positive or neutralizing antibody positive.

Preliminary antitumor activity was assessed for patients with NPC tumors and for patients with all other solid tumors. Of 32 patients with NPC, 15 (47%) had a reduction in tumor burden from baseline following nivolumab treatment (Fig. [3](#onco12963-fig-0003){ref-type="fig"}). Four patients (13%) achieved a partial response (two patients each, 3 mg/kg and 240 mg cohorts), and 17 (53%) had stable disease. The ORR and disease control rate (DCR) in this patient group were 13% (95% confidence interval \[CI\]: 4--29) and 66% (95% CI: 47--81), respectively (Table [6](#onco12963-tbl-0006){ref-type="table"}; Fig. [4](#onco12963-fig-0004){ref-type="fig"}). Patients with other solid tumor types achieved an ORR of 14% and a DCR of 36%.

The median (range) follow‐up duration for patients with NPC was 7.5 (0.8--24.7) months, with six patients (19%) having received nivolumab treatment for \>1 year. Median progression‐free survival (PFS) was 3.5 months (95% CI: 1.8--5.5 months), and median overall survival (OS) was not reached. The 3‐month PFS and OS rates were 64.2% (95% CI: 44.7--78.4) and 87.5% (95% CI: 70.0--95.1), respectively.

This study confirms the safety profile of nivolumab at 3 mg/kg in Chinese patients and is the first to report tolerability at flat doses of 240 mg and 360 mg in this population. Additionally, these data indicate that the PK of nivolumab monotherapy are ethnically insensitive. In this population of pretreated patients with advanced or recurrent disease, preliminary antitumor responses in NPC are encouraging; confirmation is required in a larger patient population.

Figures and Tables {#onco12963-sec-2001}
==================

![Patient disposition flow chart. \*Death due to septic shock considered unrelated to the study drug. ^†^Treatment status unconfirmed at the time of database lock.\
Abbreviation: AE, adverse event.](onco12963-fig-0001){#onco12963-fig-0001}

![Pharmacokinetics of nivolumab. **(A):** Mean serum concentration‐time profiles of nivolumab after single‐dose administration. **(B):** Mean serum concentration‐time profiles of nivolumab at steady state. **(C):** Geometric mean trough concentration profiles of nivolumab. For all figures: A, 3 mg/kg; B, 240 mg; C, 360 mg. Logarithmic scale. Bars indicate SD.](onco12963-fig-0002){#onco12963-fig-0002}

![Waterfall plot of best reduction from baseline in target lesions for patients with nasopharyngeal carcinoma.\
Abbreviation: PR, partial response.](onco12963-fig-0003){#onco12963-fig-0003}

![Tumor swimmer plot for the subpopulation of patients with nasopharyngeal carcinoma.\
Abbreviations: PR, partial response; SD, stable disease.](onco12963-fig-0004){#onco12963-fig-0004}

###### Baseline patient characteristics and prior cancer therapy

![](onco12963-tbl-0003){#nlm-graphic-29}

Abbreviations: ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; NPC, nasopharyngeal carcinoma; NSCLC, non‐small cell lung cancer.

###### Summary pharmacokinetic parameters of nivolumab

![](onco12963-tbl-0004){#nlm-graphic-31}

Geometric mean (% coefficient of variation \[CV\]) for all parameters except for T~max~ (median \[range\]) and t~1/2‐effective~ (mean \[% CV\]).

Abbreviations: AUC~tau~, area under the serum concentration‐time curve in one dosing interval; C~max~, maximum serum concentration; Css‐avg, average concentration over a dosing interval, calculated at steady state; C~trough~, observed trough concentration; C~tau~, concentration at the end of the dosing interval; PK, pharmacokinetic; t~1/2‐effective~, effective half‐life calculated using the formula $\frac{\tau \bullet \mathit{\ln}\left( 2 \right)}{\mathit{\ln}\left\lbrack \frac{\mathit{AI}}{\mathit{AI} - 1} \right\rbrack}$, where t is the dosing interval and AI is the ratio of AUC~tau~ at steady state to that at single dose; T~max~, time taken to reach maximum concentration.

###### Nivolumab treatment immunogenicity

![](onco12963-tbl-0005){#nlm-graphic-33}

At least one ADA‐positive (ADA+) sample relative to baseline after treatment initiation.

ADA+ samples at ≥2 consecutive timepoints.

Not PP, but ADA+ during the last sampling.

Not PP, some ADA+, with the last sampling being negative.

At least one ADA+ sample with neutralizing antibodies detected after baseline. Data shown are for patients with baseline ADA data and at least one post‐baseline ADA assessment.

Abbreviations: ADA, antidrug antibody; PP, persistent positive.

###### Antitumor responses

![](onco12963-tbl-0006){#nlm-graphic-35}

The proportion of patients whose best overall response is either a complete response or a partial response.

Confidence intervals were computed for cohorts of 10 patients or more only.

The proportion of patients with a complete response, with a partial response, or who achieved stable disease.

Abbreviations: CI, confidence interval; NPC, nasopharyngeal carcinoma.
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[^1]: Abbreviations: Q2W, once every 2 weeks; Q3W, once every 3 weeks.

[^2]: Data are median (range).

[^3]: Data represent percentage of all‐cause adverse events occurring in ≥10% across any grade up to September 25, 2018 (database lock date for analysis of clinical data). Adverse events were graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.

[^4]: Treatment‐related pancreatitis and cerebellar hemorrhage in one patient led to discontinuation of study treatment.
